Zachary Roberts
Fortuna: 362 938 $ al 31/07/2026
Fortuna: 362 938 $ al 31/07/2026
Zachary Roberts is currently President, Chief Executive Officer & Director at Allogene Therapeutics, Inc., starting in 2026.
Formerly, Dr. Roberts was Chief Medical Officer at Instil Bio, Inc. from 2020 to 2022, Vice President-Clinical Development at Kite Pharma, Inc. from 2018 to 2019, and Director-Clinical Medical Research at Amgen, Inc. in 2015.
Education includes undergraduate studies at the University of Maryland and a doctorate from the University of Maryland School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/07/2026 | 193.052 ( 0,06 % ) | 362 938 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Director Ejecutivo | 01/07/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| INSTIL BIO, INC. | Director Técnico/Científico/I+D | 11/11/2022 |
| KITE PHARMA INC | Director Técnico/Científico/I+D | 01/05/2019 |
| AMGEN INC. | Director Técnico/Científico/I+D | 01/07/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland School of Medicine
University of Maryland School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immuno-oncology | Health Technology |
Instil Bio, Inc.
Instil Bio, Inc. BiotechnologyHealth Technology Develops tumour infiltrating lymphocytes for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.